Trial Profile
Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- Acronyms S-BR
- 18 May 2017 Planned End Date changed from 1 Feb 2018 to 17 May 2017.
- 18 May 2017 Planned primary completion date changed from 1 Feb 2018 to 17 May 2017.
- 18 May 2017 Planned initiation date changed from 1 Jan 2016 to 16 Dec 2015.